ERBB2 and breast carcinoma: The purpose of this review is to summarize the background and latest evidence for the use of Trastuzumab–deruxtecan (T-DXd), a new-generation antibody drug conjugate, in advanced HER2-positive/HER2-low breast cancer, with a focus on some of the unanswered questions about the performance of this agent in clinical practice.